Innovative Molecules raises EUR20 million Series A equity financing round
Innovative Molecules, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, has closed a EUR20 million Series A equity financing round led by LSP (Life Sciences Partners).
